Maravai LifeSciences Holdings, Inc. MRVI Contract with Customer, Asset, after Allowance for Credit Loss

Contract with Customer, Asset, after Allowance for Credit Loss at other companies

Agilent TechnologiesA

——

Twist Bioscience CorporationTWST

——

IlluminaILMN

——

Other financials

Income statement

See full

Revenue$65.8M+40.5%

Gross profit$33.7M+336%

Operating income-$2.2M+95.6%

Net income-$3.7M+87.5%

EPS (diluted)-$0.02+90.5%

Balance sheet

See full

Cash & equivalents$165.9M-41.8%

Total debt$270.9M-17.1%

Total equity$211.6M-29.6%

Total assets$713.2M-25.7%

Cash flow

See full

Operating cash flow$8.7M+192%

CapEx$4.4M-1.4%

Free cash flow$4.2M+130%

Valuation

See full

Market cap$902.74M+204%

Enterprise value$1.01B+198%

P/S4.4×+3.2×

Profitability

See full

Gross margin29.3%-8.0pp

Operating margin-82.2%-16.6pp

Net margin-51.1%-9.9pp

FCF margin-25.7%—

Returns & leverage

See full

Return on equity-40.8%-4.0pp

Debt / equity1.3×+0.2×

Current ratio5.9×-0.1×

Where this comes from

Reported directly by Maravai LifeSciences Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerAssetNet.

The official record: Maravai LifeSciences Holdings, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Maravai LifeSciences Holdings, Inc.'s contract with customer, asset, after allowance for credit loss.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Maravai LifeSciences Holdings, Inc.'s contract with customer, asset, after allowance for credit loss?: Maravai LifeSciences Holdings, Inc. (MRVI) reported contract with customer, asset, after allowance for credit loss of $0 in Q1 2026.